Back to Search
Start Over
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
- Source :
-
British journal of haematology [Br J Haematol] 2019 Aug; Vol. 186 (3), pp. e35-e39. Date of Electronic Publication: 2019 Mar 31. - Publication Year :
- 2019
- Subjects :
- Angiogenesis Inhibitors administration & dosage
Angiogenesis Inhibitors adverse effects
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Dexamethasone administration & dosage
Dexamethasone adverse effects
Female
Humans
Lenalidomide administration & dosage
Lenalidomide adverse effects
Male
Neoplasm Recurrence, Local
Progression-Free Survival
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 186
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Report
- Accession number :
- 30931524
- Full Text :
- https://doi.org/10.1111/bjh.15879